Year one gets the documentaries. Year two gets silence — no dramatic drops, no shrinking-clothes montage, just a Tuesday-ish stretch of holding what you built. Talk to people deep in maintenance and a consistent, mostly encouraging picture emerges. Here's the second-year report, compiled honestly.
Key Takeaways
- Maintenance feels 'boring' — which veterans describe as the entire victory: food is quiet, weight is stable, life is about other things.
- Most maintainers land on less medication than their peak: lower doses or stretched intervals, arrived at by supervised experiment.
- At 2026 prices, maintenance costs commonly run $49–$179/month — a fraction of year-one spending for most.
- The real year-two work is psychological: replacing the progress scoreboard with a defense scoreboard, and making peace with 'ongoing.'
What It Feels Like
The near-universal report: the drama drains out. Appetite sits at a manageable hum, the scale oscillates in a small band, and the medication fades into the background of life the way any maintenance therapy does. Some people find the quiet anticlimactic at first — year one trained them to expect weekly wins. The ones who thrive reframe it: boring is what winning looks like from inside.
The Dose Question, Answered by Experiment
By mid-year-two, most maintainers have negotiated their dose downward from peak — commonly to the 0.5–1.0mg semaglutide-equivalent range, or the same dose at stretched intervals (every 10–14 days). The pattern that works is supervised experimentation: step down one notch, watch appetite and the scale for 4–6 weeks against a pre-agreed regain threshold, and either hold the new floor or step back up without drama. Plenty of people also discover they still need their full dose — which is information, not failure. Chronic conditions get maintained at the dose that maintains them.
The 2026 Cost Reality
| Maintenance pattern | Typical monthly cost |
|---|---|
| Low dose, annual-commitment flat plan | $49–$99 |
| Low-to-mid dose, month-to-month | $147–$199 |
| Full dose, flat-price plan | $179–$249 |
| Stretched intervals (same vial, more weeks) | Effectively 25–40% less than list |
For most people this is dramatically cheaper than year one, when higher doses met higher 2024–25 prices. Budgeted as a line item — like a gym membership that demonstrably works — maintenance in 2026 is financially unremarkable, which is precisely what a maintenance therapy should be.
The Identity Shift
The unexpectedly hard part of year two isn't hunger — it's narrative. "I'm losing weight" is a story with momentum; "I maintain my weight with medication" felt, to many, like an admission until they sat with the comparison: nobody frames blood-pressure medication as failing at blood pressure. The maintainers who report the most peace made that reframe explicitly, often with a clinician or therapist's help, and moved their attention to lifting numbers, hiking seasons, and lab panels — scoreboards that still move.
Maintenance-Priced Programs
Telos Rx — Semaglutide
Compounded semaglutide — from $49/mo on 12-month plans
Flat pricing regardless of dose, with month-to-month through annual commitment tiers.
Compounded medications are not FDA-approved.
Visit Telos Rx Paid linkWellorithm
Oral tablets — sema $147/mo, tirz $249/mo
The lowest published oral compounded pricing we currently track.
Compounded medications are not FDA-approved.
Visit Wellorithm Paid linkEden
Oral drops + gummies — sema $249/mo ($149 first month)
Oral compounded formats including drops and gummies, with a discounted first month.
Compounded medications are not FDA-approved.
Visit Eden Paid linkYear two is quieter, cheaper, and more negotiable than year one — and it's the year that decides whether year one mattered. Boring, it turns out, is the goal.
Affiliate disclosure: Links marked "Paid link" are affiliate links. We may earn a commission if you sign up through them, at no extra cost to you. This supports our independent research.
Compounded medication notice: Compounded medications are not FDA-approved. The FDA does not verify the safety, effectiveness, or quality of compounded drugs before they are marketed. Brand-name alternatives (Wegovy, Ozempic, Zepbound, Rybelsus) are FDA-approved.
Medical disclaimer: This article is for informational purposes only and is not medical advice. GLP-1 medications are prescription drugs. Always consult a licensed healthcare provider about diagnosis, treatment, dosing, and whether these medications are appropriate for you.